These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9479369)

  • 1. [Therapeutic approach in sarcoma of corpus uteri].
    Bokhman IaV; Urmancheeva AF; Gershanovich ML; Zel'dovich DR; Kutusheva GF
    Vopr Onkol; 1997; 43(6):645-50. PubMed ID: 9479369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical analysis of 153 uterine sarcomas].
    Bai P; Sun J; Chao H
    Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):163-7. PubMed ID: 9596892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of patients with sarcoma of the uterus].
    Bokhman IaV; Urmancheeva AF
    Vopr Onkol; 1989; 35(10):1245-51. PubMed ID: 2596071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
    Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
    Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
    Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
    Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of 105 cases with uterine sarcoma.
    Yoney A; Eren B; Eskici S; Salman A; Unsal M
    Bull Cancer; 2008 Mar; 95(3):E10-7. PubMed ID: 18390406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and outcome in women with uterine sarcoma.
    Denschlag D; Masoud I; Stanimir G; Gilbert L
    Eur J Surg Oncol; 2007 Feb; 33(1):91-5. PubMed ID: 17174517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine sarcoma: prognostic factors and treatment evaluation.
    Naaman Y; Shveiky D; Ben-Shachar I; Shushan A; Mejia-Gomez J; Benshushan A
    Isr Med Assoc J; 2011 Feb; 13(2):76-9. PubMed ID: 21443030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Malignant mixed mesodermal tumors of the ovary: a clinical analysis of 12 cases].
    Li H; Shi S; Zhang W
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):460-2. PubMed ID: 10920946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment and prognosis of low-grade malignant endometrial stromal sarcoma].
    Ma SK; Zhang HT; Wu LY; Liu LY; Li B
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):74-8. PubMed ID: 17575701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
    Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
    Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments.
    Chauveinc L; Deniaud E; Plancher C; Sastre X; Amsani F; de la Rochefordiere A; Rozemberg H; Clough KB
    Gynecol Oncol; 1999 Feb; 72(2):232-7. PubMed ID: 10021306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.
    Clavero JM; Deschamps C; Cassivi SD; Allen MS; Nichols FC; Barrette BA; Larson DR; Pairolero PC
    Ann Thorac Surg; 2006 Jun; 81(6):2004-7. PubMed ID: 16731120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiological factors, treatment and prognosis of uterine sarcomas: 14 cases at the Cancer Institute of Dakar].
    Dem A; Kasse AA; Diop M; Cisse B; Toure P
    Dakar Med; 2000; 45(1):85-8. PubMed ID: 14666799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on treatment of uterine sarcoma.
    Nam JH; Park JY
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):36-42. PubMed ID: 19923988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of patients with uterine sarcoma: a debated clinical challenge.
    Gadducci A; Cosio S; Romanini A; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):129-42. PubMed ID: 17706430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.
    Bodner K; Bodner-Adler B; Obermair A; Windbichler G; Petru E; Mayerhofer S; Czerwenka K; Leodolter S; Kainz C; Mayerhofer K
    Gynecol Oncol; 2001 May; 81(2):160-5. PubMed ID: 11330943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
    Havrilesky LJ; Cragun JM; Calingaert B; Alvarez Secord A; Valea FA; Clarke-Pearson DL; Berchuck A; Soper JT
    Gynecol Oncol; 2007 Feb; 104(2):401-5. PubMed ID: 17014898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.